Blockchain Registration Transaction Record

Kairos Pharma Reports 86% Clinical Benefit in Prostate Cancer Trial

Kairos Pharma reports 86% clinical benefit in Phase 2 prostate cancer trial with ENV105. No dose-limiting toxicities observed. Read about breakthrough cancer treatment targeting CD105 resistance.

This development represents a potential breakthrough in cancer treatment, particularly for patients with advanced metastatic prostate cancer who have limited therapeutic options. The 86% clinical benefit rate with no dose-limiting toxicities suggests ENV105 could significantly extend survival while maintaining quality of life for cancer patients. For the broader oncology field, the successful targeting of CD105 to reverse drug resistance opens new avenues for treating various cancers where resistance to standard therapies remains a major challenge. This approach could transform how multiple cancer types are treated, potentially making existing therapies more effective and durable. For investors and the healthcare industry, Kairos Pharma's progress demonstrates the growing potential of precision oncology approaches that address fundamental mechanisms of treatment resistance.